# pazopanib_NCRCC,Ph2 STUDY

> **NCT01538238** · PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 10 (actual)

## Conditions studied

- Locally Advanced or Metastatic Non-clear Cell Type Renal Cell Carcinoma

## Interventions

- **DRUG:** pazopanib

## Key facts

- **NCT ID:** NCT01538238
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-02
- **Primary completion:** 2015-02-28
- **Final completion:** 2015-11-14
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2017-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01538238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01538238, "pazopanib_NCRCC,Ph2 STUDY". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01538238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*